Astal Laboratories Limited has successfully completed the acquisition of Sriven Pharmachem India Private Limited through a strategic share allotment worth ₹277.17 crores. The pharmaceutical company allotted 3.04 crore equity shares on January 14, 2026, making Sriven Pharmachem a wholly owned subsidiary and significantly expanding its manufacturing capabilities in active pharmaceutical ingredients.

Strategic Acquisition Through Share Swap

The company's board approved the allotment of 3,04,25,632 equity shares to acquire 100% stake in Sriven Pharmachem India Private Limited. The acquisition was executed through a combination of share swap and cash consideration, with the majority handled through preferential allotment.

The acquisition includes a small cash component of ₹29.63 lakhs paid to Ms. Niharika Bansal for 32,555 equity shares, as she was disqualified from the preferential allotment due to regulatory compliance issues under SEBI ICDR Regulations.

Target Company Profile and Performance

Sriven Pharmachem India Private Limited, incorporated on March 5, 2015, specializes in developing and producing high-profile drug intermediates and specialty chemicals. The company operates in the pharmaceutical industry with a focus on manufacturing active pharmaceutical ingredients and intermediates.

The target company has an authorized share capital of ₹31.00 crores divided into 3.10 crore equity shares of ₹10 each, with a paid-up capital of ₹30.46 crores.

Strategic Benefits and Business Expansion

The acquisition aligns with Astal Laboratories' long-term vision of becoming a fully integrated pharmaceutical manufacturing company. The transaction will enable the company to expand its product offerings and strengthen its position in the pharmaceutical sector through enhanced manufacturing capabilities in APIs and specialty chemicals.

Regulatory Compliance and Approvals

The acquisition was executed following comprehensive regulatory approvals and compliance with SEBI regulations. The transaction involved related party elements, as Mr. Sudheer Karna Kankanala, Director of Astal Laboratories, holds shares in the target company.

The company must complete post-allotment compliance requirements, including submission of listing applications within twenty days as per SEBI regulations. This acquisition represents a significant milestone in Astal Laboratories' growth strategy and strengthens its pharmaceutical manufacturing capabilities.

Astal Laboratories Limited has entered into a strategic partnership with Switzerland-based Immuna Therapeutics GmbH through a Letter of Intent (LOI) for exclusive India rights to next-generation CAR-T cell therapies. The collaboration aims to target ₹3,000.00 crore incremental revenue through localized manufacturing and technology transfer.

Partnership Details

The partnership provides Astal Laboratories with exclusive rights to advanced CAR-T cell therapies, including TriCAR-T platforms, specifically for the Indian market. The comprehensive partnership structure covers multiple aspects of the therapy development and commercialization process.

Revenue Projections and Market Impact

Astal Laboratories has significantly revised its revenue expectations, now estimating the collaboration will generate incremental revenue of approximately ₹3,000.00 crore upon implementation. This substantial projection represents a ten-fold increase from earlier estimates, reflecting the enhanced scope and potential of the partnership.

The partnership positions the company strategically within India's immuno-oncology sector, particularly in the emerging cell and gene therapy segment. The localized manufacturing approach is expected to enhance accessibility to these advanced treatments for Indian patients while creating substantial revenue opportunities.

Strategic Significance

This collaboration aligns with Astal Laboratories' long-term strategy to expand into high-value advanced therapies and cell and gene therapy platforms. The partnership establishes the company at the forefront of next-generation immuno-oncology treatments in India, with the technology transfer component ensuring comprehensive knowledge and capability development.

The initiative creates a scalable platform for future cell therapy programs, potentially opening doors for additional therapeutic developments. The focus on CAR-T cell therapies represents a significant advancement in cancer treatment options, particularly for patients with certain blood cancers and solid tumors.

Implementation Framework

The proposed collaboration encompasses a comprehensive approach to bringing advanced CAR-T therapies to the Indian market. Technology transfer from Immuna Therapeutics will enable Astal Laboratories to establish local manufacturing capabilities, reducing dependency on imports and potentially lowering treatment costs.

The clinical development component ensures that therapies will be appropriately tested and validated for the Indian patient population, while the commercialization strategy focuses on making these advanced treatments accessible across the country through localized production and distribution networks.